drugset / Trial / NCT00914862

Pharmacokinetic and Safety of Ramelteon Between Adolescents With Insomnia and Healthy Adults

NCT00914862

Phase 1 Completed 56 enrolled Takeda
RandomizedParallel-groupOpen-label

Summary

The purpose of this study is to determine the pharmacokinetic profile, safety, and tolerability of ramelteon in adolescents with insomnia, children with Attention Deficit Hyperactivity Disorder (ADHD) associated with insomnia and gender- and race-matched healthy adults.

Timeline

Start
2009-11
Primary completion
2011-03
Completion
2011-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Ramelteon Unknown 4 mg Oral
Subject Ramelteon Unknown 8 mg Oral

Indications